Good evening and welcome to Markets Desk, your closing bell rundown on what moved the needle today.
Stocks climbed after Washington and Tehran reached a preliminary nuclear agreement, lifting sentiment across equity markets. The deal eases near-term fears around oil supply disruptions through the Strait of Hormuz, but analysts are quick to note that key questions around Israeli opposition, verification mechanisms, and a formal Geneva signing remain very much open. Traders are pricing in optimism cautiously.
Shifting to a story drawing sharp attention in IPO markets, SpaceX has reportedly shattered the record for the largest public offering in Wall Street history, but critics are raising serious red flags. Language buried in the prospectus is drawing comparisons to structures that historically disadvantage retail investors, concentrating control firmly with insiders while offering ordinary buyers limited governance recourse. Caveat emptor in a very big way.
Meanwhile, in pharma, Alkermes received orphan drug designation for its compound alixorexton, an oral treatment targeting narcolepsy type one, narcolepsy type two, and idiopathic hypersomnia. Orphan status unlocks accelerated review pathways and extended market exclusivity, both meaningful catalysts for a mid-cap biotech looking to establish a foothold in the sleep disorder space. Shares responded positively on the news.
That's the tape. Markets Desk, signing off the floor.
